블로그

• [U.S. FDA] FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Adv Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD blog.naver.com · 2026.08.07